Affiliate Professor, Department of Physiology & Pharmacology
OHSU

Leah Frye is the co-founder of the Drug Discovery Group at the physics-based software platform company, Schrödinger. She led the drug discovery team from the time she joined the company in 2001 to 2019, rising to the level of Vice President, and then transitioned back into hands on drug discovery research as a Distinguished Fellow. She is also an Affiliate Professor in the Department of Chemical Physiology and Biochemistry at the Oregon Health & Sciences University. She received her PhD in Synthetic Organic Chemistry from The Johns Hopkins University in 1984, and was an NIH Individual NRSA Postdoctoral Fellow in the Department of Pharmacology and Experimental Therapeutics at The Johns Hopkins School of Medicine. Before joining Schrödinger, Leah was a Principal Scientist at Boehringer Ingelheim Pharmaceuticals and prior to that she was an Associate Professor of Chemistry at Rensselaer Polytechnic Institute.

Summits Attended: 2020 Debug

Diverse representation is a priority for us. We're proud to say that our Summit speakers are 80% queer women, 50% women of color, 25% Black & Latinx, and 15% transgender and gender nonconforming.